March 28 (Reuters) - Palatin Technologies Inc PTN.A:
PALATIN ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 ULCERATIVE COLITIS (UC) STUDY OF ORAL MELANOCORTIN-1 RECEPTOR AGONIST PL8177
PALATIN: CLINICAL REMISSION ACHIEVED IN 33% OF PL8177-TREATED PATIENTS VERSUS 0% ON PLACEBO AFTER EIGHT WEEKS OF TREATMENT
PALATIN TECHNOLOGIES INC: SAFETY AND TOLERABILITY: EXCELLENT, WITH NO ADVERSE EVENTS
PALATIN: STATISTICALLY SIGNIFICANT CLINICAL RESPONSE SEEN IN 78% OF PL8177-TREATED PATIENTS VERSUS 33% ON PLACEBO AFTER 8 WEEKS OF TREATMENT
Source text: ID:nPn4BYDMga
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。